

Rhinovirus Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre- clinical and Clinical Drugs

<https://marketpublishers.com/r/R23B5FB53D93EN.html>

Date: October 2019

Pages: 50

Price: US\$ 1,699.00 (Single User License)

ID: R23B5FB53D93EN

Abstracts

Rhinovirus Infections Drug pipeline report- 2020 is an annual R&D review of Rhinovirus Infections pipeline candidates. The report presents the current status of all major Rhinovirus Infections therapeutic compounds. Detailed insights into Rhinovirus Infections pipeline development, current status, companies, drug profiles and Rhinovirus Infections preclinical and clinical trials are included.

2020 Rhinovirus Infections Pipeline Market Insights

Rhinovirus Infections disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Rhinovirus Infections therapies, pipeline by phase and others are included.

Rhinovirus Infections pipeline Drug profiles-

Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Rhinovirus Infections Therapeutic Drug candidates

Both active and inactive Rhinovirus Infections pipeline drug candidates are included in the report

Rhinovirus Infections Clinical Trials and preclinical Studies

Rhinovirus Infections In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are

provided.

Rhinovirus Infections pipeline market developments

Rhinovirus Infections Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Rhinovirus Infections pipeline companies in active development

The report analyzes Rhinovirus Infections pipeline of the below companies-

ARMS Pharmaceutical LLC, AstraZeneca Plc, Biological Mimetics Inc, Enyo Pharma SA, Gilead Sciences Inc, Haplogen GmbH, Meissa Vaccines Inc, Polyrizon Ltd, PrEP Biopharm Ltd, Prokarium Ltd, Romark Laboratories LC, Sagimet Biosciences, Secarna Pharmaceuticals GmbH&Co.KG, Viravaxx AG

Report Coverage

What to look out for in 2020

Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot

Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies

14 Companies investing in Rhinovirus Infections pipeline from discovery stage to pre-registration phase are included

Drug profiles

Over 10 details of each Rhinovirus Infections pipeline candidate are included

Company Profiles

Business overview and contact details of all companies operating in the industry are provided

Market Developments

News, Developments and other recent industry developments are included

Contents

1. RHINOVIRUS INFECTIONS PIPELINE MARKET INSIGHTS, 2020

- 1.1 Rhinovirus Infections Disease Overview
- 1.2 Rhinovirus Infections Drug Pipeline Snapshot, 2020
 - 1.2.1 Rhinovirus Infections Pipeline Drugs by Phase
 - 1.2.2 Rhinovirus Infections Pipeline Drugs by Company
 - 1.2.3 Rhinovirus Infections Pipeline Drugs by Mechanism of Action
 - 1.2.4 Rhinovirus Infections Pipeline Drugs by Route of Administration

2. RHINOVIRUS INFECTIONS COMPANY WISE PIPELINE DETAILS

ARMS Pharmaceutical LLC Rhinovirus Infections Pipeline Drugs

- Company Profile

- Drug Candidate Details

AstraZeneca Plc Rhinovirus Infections Pipeline Drugs

- Company Profile

- Drug Candidate Details

Biological Mimetics Inc Rhinovirus Infections Pipeline Drugs

- Company Profile

- Drug Candidate Details

Enyo Pharma SA Rhinovirus Infections Pipeline Drugs

- Company Profile

- Drug Candidate Details

Gilead Sciences Inc Rhinovirus Infections Pipeline Drugs

- Company Profile

- Drug Candidate Details

Haplogen GmbH Rhinovirus Infections Pipeline Drugs

- Company Profile

- Drug Candidate Details

Meissa Vaccines Inc Rhinovirus Infections Pipeline Drugs

- Company Profile

- Drug Candidate Details

Polyrizon Ltd Rhinovirus Infections Pipeline Drugs

- Company Profile

- Drug Candidate Details

PrEP Biopharm Ltd Rhinovirus Infections Pipeline Drugs

- Company Profile

Drug Candidate Details

Prokarium Ltd Rhinovirus Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Romark Laboratories LC Rhinovirus Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Sagimet Biosciences Rhinovirus Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Secarna Pharmaceuticals GmbH&Co.KG Rhinovirus Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Viravaxx AG Rhinovirus Infections Pipeline Drugs

Company Profile

Drug Candidate Details

3. RHINOVIRUS INFECTIONS DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles

3.2 Phase 1 Drug Profiles

3.3 Phase 2 Drug Profiles

3.4 Phase 3 Drug Profiles

4. RHINOVIRUS INFECTIONS PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology

5.2 Publisher Expertize

5.3 Contacts

I would like to order

Product name: Rhinovirus Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

Product link: <https://marketpublishers.com/r/R23B5FB53D93EN.html>

Price: US\$ 1,699.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R23B5FB53D93EN.html>